Volume 22: Issue 1 (Apr 2023): Disorders of Divalent Ions, Renal Bone Disease and Nephrolithiasis

Itano Y, Kato S, Tsuboi M, Kasuga H, Tsuruta Y, Sato F, et al.: A prospective, randomized clinical trial of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism (the DUET Trial). Kidney Int Rep 5: 2168–2177, 2020 PubMed

• PubMed
Itano Y, Kato S, Tsuboi M, Kasuga H, Tsuruta Y, Sato F, et al.: A prospective, randomized clinical trial of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism (the DUET Trial). Kidney Int Rep 5: 2168–2177, 2020 PubMed)| false
• Search Google Scholar
• Export Citation

Shoji T, Nakatani S, Kabata D, Mori K, Shintani A, Yoshida H, et al.: Comparative effects of etelcalcetide and maxacalcitol on serum calcification propensity in secondary hyperparathyroidism: A randomized clinical trial. Clin J Am Soc Nephrol 16: 599–612, 2021 PubMed

• PubMed
Shoji T, Nakatani S, Kabata D, Mori K, Shintani A, Yoshida H, et al.: Comparative effects of etelcalcetide and maxacalcitol on serum calcification propensity in secondary hyperparathyroidism: A randomized clinical trial. Clin J Am Soc Nephrol 16: 599–612, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

Dörr K, Kammer M, Reindl-Schwaighofer R, Lorenz M, Prikoszovich T, Marculescu R, et al.: Randomized trial of etelcalcetide for cardiac hypertrophy in hemodialysis. Circ Res 128: 1616–1625, 2021 PubMed

• PubMed
Dörr K, Kammer M, Reindl-Schwaighofer R, Lorenz M, Prikoszovich T, Marculescu R, et al.: Randomized trial of etelcalcetide for cardiac hypertrophy in hemodialysis. Circ Res 128: 1616–1625, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

Karaboyas A, Muenz D, Fuller DS, Desai P, Lin TC, Robinson BM, et al.: Etelcalcetide utilization, dosing titration, and chronic kidney disease-mineral and bone disease (CKD-MBD) marker responses in US hemodialysis patients. Am J Kidney Dis 79: 362–373, 2022 PubMed

• PubMed
Karaboyas A, Muenz D, Fuller DS, Desai P, Lin TC, Robinson BM, et al.: Etelcalcetide utilization, dosing titration, and chronic kidney disease-mineral and bone disease (CKD-MBD) marker responses in US hemodialysis patients. Am J Kidney Dis 79: 362–373, 2022 PubMed)| false
• Search Google Scholar
• Export Citation

Yokoyama K, Fukagawa M, Shigematsu T, Akiba T, Yoshikawa K, Tsuchiya A, et al.: Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: Results of a post-marketing surveillance in Japan. Clin Exp Nephrol 25: 66–79, 2021 PubMed

• PubMed
Yokoyama K, Fukagawa M, Shigematsu T, Akiba T, Yoshikawa K, Tsuchiya A, et al.: Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: Results of a post-marketing surveillance in Japan. Clin Exp Nephrol 25: 66–79, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

Goodman WG, Ward DT, Martin KJ, Drayer D, Moore C, Xu J, et al.: Activation of the calcium receptor by calcimimetic agents is preserved despite modest attenuating effects of hyperphosphatemia. J Am Soc Nephrol 33: 201–212, 2022 PubMed

• PubMed
Goodman WG, Ward DT, Martin KJ, Drayer D, Moore C, Xu J, et al.: Activation of the calcium receptor by calcimimetic agents is preserved despite modest attenuating effects of hyperphosphatemia. J Am Soc Nephrol 33: 201–212, 2022 PubMed)| false
• Search Google Scholar
• Export Citation

Centeno PP, Herberger A, Mun HC, Tu C, Nemeth EF, Chang W, et al.: Phosphate acts directly on the calcium-sensing receptor to stimulate parathyroid hormone secretion. Nat Commun 10: 4693, 2019 PubMed

• PubMed
Centeno PP, Herberger A, Mun HC, Tu C, Nemeth EF, Chang W, et al.: Phosphate acts directly on the calcium-sensing receptor to stimulate parathyroid hormone secretion. Nat Commun 10: 4693, 2019 PubMed)| false
• Search Google Scholar
• Export Citation

Damrath JG, Moe SM, Wallace JM: Calcimimetics alter periosteal and perilacunar bone matrix composition and material properties in early chronic kidney disease. J Bone Miner Res 37: 1297–1306, 2022 PubMed

• PubMed
Damrath JG, Moe SM, Wallace JM: Calcimimetics alter periosteal and perilacunar bone matrix composition and material properties in early chronic kidney disease. J Bone Miner Res 37: 1297–1306, 2022 PubMed)| false
• Search Google Scholar
• Export Citation

Bernardor J, Flammier S, Ranchin B, Gaillard S, Platel D, Peyruchaud O, et al.: Inhibition of osteoclast differentiation by 1.25-D and the calcimimetic KP2326 reveals 1.25-D resistance in advanced CKD. J Bone Miner Res 35: 2265–2274, 2020 PubMed

• PubMed
Bernardor J, Flammier S, Ranchin B, Gaillard S, Platel D, Peyruchaud O, et al.: Inhibition of osteoclast differentiation by 1.25-D and the calcimimetic KP2326 reveals 1.25-D resistance in advanced CKD. J Bone Miner Res 35: 2265–2274, 2020 PubMed)| false
• Search Google Scholar
• Export Citation

Díaz-Tocados JM, Rodríguez-Ortiz ME, Almadén Y, Pineda C, Martínez-Moreno JM, Herencia C, et al.: Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration. Kidney Int 95: 1064–1078, 2019 PubMed

• PubMed
Díaz-Tocados JM, Rodríguez-Ortiz ME, Almadén Y, Pineda C, Martínez-Moreno JM, Herencia C, et al.: Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration. Kidney Int 95: 1064–1078, 2019 PubMed)| false
• Search Google Scholar
• Export Citation

Mary A, Objois T, Brazier M, Bennis Y, Boudot C, Lenglet G, et al.: Decreased monocyte calcium sensing receptor expression in patients with chronic kidney disease is associated with impaired monocyte ability to reduce vascular calcification. Kidney Int 99: 1382–1391, 2021 PubMed

• PubMed
Mary A, Objois T, Brazier M, Bennis Y, Boudot C, Lenglet G, et al.: Decreased monocyte calcium sensing receptor expression in patients with chronic kidney disease is associated with impaired monocyte ability to reduce vascular calcification. Kidney Int 99: 1382–1391, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

Imafuku T, Tanaka M, Tokunaga K, Miyamura S, Kato H, Tanaka S, et al.: Effect of cinacalcet on the redox status of albumin in secondary hyperparathyroidism patients receiving hemodialysis. Biol Pharm Bull 43: 1583–1590, 2020 PubMed

• PubMed
Imafuku T, Tanaka M, Tokunaga K, Miyamura S, Kato H, Tanaka S, et al.: Effect of cinacalcet on the redox status of albumin in secondary hyperparathyroidism patients receiving hemodialysis. Biol Pharm Bull 43: 1583–1590, 2020 PubMed)| false
• Search Google Scholar
• Export Citation

Fadda G, Germain MJ, Broumand V, Nguyen A, McGarvey N, Gitlin M, et al.: Real-world assessment: Clinical effectiveness and safety of extended-release calcifediol. Am J Nephrol 52: 798–807, 2021 PubMed

• PubMed
Fadda G, Germain MJ, Broumand V, Nguyen A, McGarvey N, Gitlin M, et al.: Real-world assessment: Clinical effectiveness and safety of extended-release calcifediol. Am J Nephrol 52: 798–807, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

Haarhaus M, Evenepoel P; European Renal Osteodystrophy (EUROD) workgroup; Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) working group of the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA): Differentiating the causes of adynamic bone in advanced chronic kidney disease informs osteoporosis treatment. Kidney Int 100: 546–558, 2021 PubMed

• PubMed
Haarhaus M, Evenepoel P; European Renal Osteodystrophy (EUROD) workgroup; Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) working group of the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA): Differentiating the causes of adynamic bone in advanced chronic kidney disease informs osteoporosis treatment. Kidney Int 100: 546–558, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

Chen CL, Chen NC, Wu FZ, Wu MT: Impact of denosumab on cardiovascular calcification in patients with secondary hyperparathyroidism undergoing dialysis: A pilot study. Osteoporos Int 31: 1507–1516, 2020 PubMed

• PubMed
Chen CL, Chen NC, Wu FZ, Wu MT: Impact of denosumab on cardiovascular calcification in patients with secondary hyperparathyroidism undergoing dialysis: A pilot study. Osteoporos Int 31: 1507–1516, 2020 PubMed)| false
• Search Google Scholar
• Export Citation

Ott SM, Malluche HH, Jorgetti V, Elder GJ: Importance of bone turnover for therapeutic decisions in patients with CKD-MBD. Kidney Int 100: 502–505, 2021 PubMed

• PubMed
Ott SM, Malluche HH, Jorgetti V, Elder GJ: Importance of bone turnover for therapeutic decisions in patients with CKD-MBD. Kidney Int 100: 502–505, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

van der Plas W, Kruijff S, Sidhu SB, Delbridge LW, Sywak MS, Engelsman AF: Parathyroidectomy for patients with secondary hyperparathyroidism in a changing landscape for the management of end-stage renal disease. Surgery 169: 275–281, 2021 PubMed

• PubMed
van der Plas W, Kruijff S, Sidhu SB, Delbridge LW, Sywak MS, Engelsman AF: Parathyroidectomy for patients with secondary hyperparathyroidism in a changing landscape for the management of end-stage renal disease. Surgery 169: 275–281, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

Zhang DL, Chen S, Gao MZ, Lin YC, Hong FY, You ZH, et al.: Ultrasound-guided radiofrequency ablation: A new attempt to the treatment of refractory hyperparathyroidism secondary to chronic kidney disease. Kidney Int Rep 7: 282–288, 2021 PubMed

• PubMed
Zhang DL, Chen S, Gao MZ, Lin YC, Hong FY, You ZH, et al.: Ultrasound-guided radiofrequency ablation: A new attempt to the treatment of refractory hyperparathyroidism secondary to chronic kidney disease. Kidney Int Rep 7: 282–288, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

Zhao S, Gan W, Xie W, Cao J, Zhang L, Wen P, et al.: A single-center experience of parathyroidectomy in 1500 cases for secondary hyperparathyroidism: A retrospective study. Ren Fail 44: 23–29, 2022 PubMed

• PubMed
Zhao S, Gan W, Xie W, Cao J, Zhang L, Wen P, et al.: A single-center experience of parathyroidectomy in 1500 cases for secondary hyperparathyroidism: A retrospective study. Ren Fail 44: 23–29, 2022 PubMed)| false
• Search Google Scholar
• Export Citation

Ishani A, Liu J, Wetmore JB, Lowe KA, Do T, Bradbury BD, et al.: Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis. Clin J Am Soc Nephrol 10: 90–97, 2015 PubMed

• PubMed
Ishani A, Liu J, Wetmore JB, Lowe KA, Do T, Bradbury BD, et al.: Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis. Clin J Am Soc Nephrol 10: 90–97, 2015 PubMed)| false
• Search Google Scholar
• Export Citation

Williams-Karnesky RL, Krumeich L, Wachtel H, Fraker DL, Wirtalla C, Venuto FA, et al.: Data to inform counseling on parathyroidectomy for secondary hyperparathyroidism of renal origin. Surgery 171: 63–68, 2022 PubMed

• PubMed
Williams-Karnesky RL, Krumeich L, Wachtel H, Fraker DL, Wirtalla C, Venuto FA, et al.: Data to inform counseling on parathyroidectomy for secondary hyperparathyroidism of renal origin. Surgery 171: 63–68, 2022 PubMed)| false
• Search Google Scholar
• Export Citation

Phimphilai M, Inya S, Manosroi W: A predictive risk score to diagnose hypocalcemia after parathyroidectomy in patients with secondary hyperparathyroidism: A 22-year retrospective cohort study. Sci Rep 12: 9548, 2022 PubMed

• PubMed
Phimphilai M, Inya S, Manosroi W: A predictive risk score to diagnose hypocalcemia after parathyroidectomy in patients with secondary hyperparathyroidism: A 22-year retrospective cohort study. Sci Rep 12: 9548, 2022 PubMed)| false
• Search Google Scholar
• Export Citation

Siqueira FR, Oliveira KC, Dominguez WV, Truyts CAM, Moysés RMA, Dos Reis LM, et al.: Effect of parathyroidectomy on bone tissue biomarkers and body composition in patients with chronic kidney disease and secondary hyperparathyroidism. Eur J Clin Nutr 75: 1126–1133, 2021 PubMed

• PubMed
Siqueira FR, Oliveira KC, Dominguez WV, Truyts CAM, Moysés RMA, Dos Reis LM, et al.: Effect of parathyroidectomy on bone tissue biomarkers and body composition in patients with chronic kidney disease and secondary hyperparathyroidism. Eur J Clin Nutr 75: 1126–1133, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

Jimeno-Fraile J, Cao H, Sancho-Insenser J, Lorente-Poch L, Sitges-Serra A: Muscle strength, physical performance, and metabolic changes after subtotal parathyroidectomy for secondary hyperparathyroidism. Surgery 169: 846–851, 2021 PubMed

• PubMed
Jimeno-Fraile J, Cao H, Sancho-Insenser J, Lorente-Poch L, Sitges-Serra A: Muscle strength, physical performance, and metabolic changes after subtotal parathyroidectomy for secondary hyperparathyroidism. Surgery 169: 846–851, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

Komaba H, Hamano T, Fujii N, Moriwaki K, Wada A, Masakane I, et al.: Parathyroidectomy vs cinacalcet among patients undergoing hemodialysis. J Clin Endocrinol Metab 107: 2016–2025, 2022 PubMed

• PubMed
Komaba H, Hamano T, Fujii N, Moriwaki K, Wada A, Masakane I, et al.: Parathyroidectomy vs cinacalcet among patients undergoing hemodialysis. J Clin Endocrinol Metab 107: 2016–2025, 2022 PubMed)| false
• Search Google Scholar
• Export Citation

Saeseow S, Vantanasiri K, Suvikapakornkul R, Sukarayothin T, Apirakkittikul N, Disthabanchong S: Parathyroidectomy is associated with slow progression of vascular calcification in maintenance haemodialysis patients: A propensity score-matched case-control study. Nephrology (Carlton) 27: 355–362, 2022 PubMed

• PubMed
Saeseow S, Vantanasiri K, Suvikapakornkul R, Sukarayothin T, Apirakkittikul N, Disthabanchong S: Parathyroidectomy is associated with slow progression of vascular calcification in maintenance haemodialysis patients: A propensity score-matched case-control study. Nephrology (Carlton) 27: 355–362, 2022 PubMed)| false
• Search Google Scholar
• Export Citation

Xu Y, Evans M, Soro M, Barany P, Carrero JJ: Secondary hyperparathyroidism and adverse health outcomes in adults with chronic kidney disease. Clin Kidney J 14: 2213–2220, 2021 PubMed

• PubMed
Xu Y, Evans M, Soro M, Barany P, Carrero JJ: Secondary hyperparathyroidism and adverse health outcomes in adults with chronic kidney disease. Clin Kidney J 14: 2213–2220, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

Bozic M, Diaz-Tocados JM, Bermudez-Lopez M, Forné C, Martinez C, Fernandez E, et al.: Independent effects of secondary hyperparathyroidism and hyperphosphataemia on chronic kidney disease progression and cardiovascular events: An analysis from the NEFRONA cohort. Nephrol Dial Transplant 37: 663–672, 2022 PubMed

• PubMed
Bozic M, Diaz-Tocados JM, Bermudez-Lopez M, Forné C, Martinez C, Fernandez E, et al.: Independent effects of secondary hyperparathyroidism and hyperphosphataemia on chronic kidney disease progression and cardiovascular events: An analysis from the NEFRONA cohort. Nephrol Dial Transplant 37: 663–672, 2022 PubMed)| false
• Search Google Scholar
• Export Citation

Liu CT, Hsu SC, Hsieh HL, Chen CH, Chen CY, Sue YM, et al.: Parathyroid hormone induces transition of myofibroblasts in arteriovenous fistula and increases maturation failure. Endocrinology 162: bqab044, 2021 PubMed

• PubMed
Liu CT, Hsu SC, Hsieh HL, Chen CH, Chen CY, Sue YM, et al.: Parathyroid hormone induces transition of myofibroblasts in arteriovenous fistula and increases maturation failure. Endocrinology 162: bqab044, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

Tabibzadeh N, Karaboyas A, Robinson BM, Csomor PA, Spiegel DM, Evenepoel P, et al.: The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation. Nephrol Dial Transplant 36: 160–169, 2021 PubMed

• PubMed
Tabibzadeh N, Karaboyas A, Robinson BM, Csomor PA, Spiegel DM, Evenepoel P, et al.: The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation. Nephrol Dial Transplant 36: 160–169, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

Komaba H, Zhao J, Yamamoto S, Nomura T, Fuller DS, McCullough KP, et al.: Secondary hyperparathyroidism, weight loss, and longer term mortality in haemodialysis patients: Results from the DOPPS. J Cachexia Sarcopenia Muscle 12: 855–865, 2021 PubMed

• PubMed
Komaba H, Zhao J, Yamamoto S, Nomura T, Fuller DS, McCullough KP, et al.: Secondary hyperparathyroidism, weight loss, and longer term mortality in haemodialysis patients: Results from the DOPPS. J Cachexia Sarcopenia Muscle 12: 855–865, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

Egstrand S, Nordholm A, Morevati M, Mace ML, Hassan A, Naveh-Many T, et al.: A molecular circadian clock operates in the parathyroid gland and is disturbed in chronic kidney disease associated bone and mineral disorder. Kidney Int 98: 1461–1475, 2020 PubMed

• PubMed
Egstrand S, Nordholm A, Morevati M, Mace ML, Hassan A, Naveh-Many T, et al.: A molecular circadian clock operates in the parathyroid gland and is disturbed in chronic kidney disease associated bone and mineral disorder. Kidney Int 98: 1461–1475, 2020 PubMed)| false
• Search Google Scholar
• Export Citation

Egstrand S, Mace ML, Morevati M, Nordholm A, Engelholm LH, Thomsen JS, et al.: Hypomorphic expression of parathyroid Bmal1 disrupts the internal parathyroid circadian clock and increases parathyroid cell proliferation in response to uremia. Kidney Int 101: 1232–1250, 2022 PubMed

• PubMed
Egstrand S, Mace ML, Morevati M, Nordholm A, Engelholm LH, Thomsen JS, et al.: Hypomorphic expression of parathyroid Bmal1 disrupts the internal parathyroid circadian clock and increases parathyroid cell proliferation in response to uremia. Kidney Int 101: 1232–1250, 2022 PubMed)| false
• Search Google Scholar
• Export Citation

Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, et al.: Diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder: Synopsis of the kidney disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update. Ann Intern Med 168: 422–430, 2018 PubMed

• PubMed
Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, et al.: Diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder: Synopsis of the kidney disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update. Ann Intern Med 168: 422–430, 2018 PubMed)| false
• Search Google Scholar
• Export Citation

Ruospo M, Palmer SC, Natale P, Craig JC, Vecchio M, Elder GJ, et al.: Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev 8: CD006023, 2018 PubMed

• PubMed
Ruospo M, Palmer SC, Natale P, Craig JC, Vecchio M, Elder GJ, et al.: Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev 8: CD006023, 2018 PubMed)| false
• Search Google Scholar
• Export Citation

Scialla JJ, Kendrick J, Uribarri J, Kovesdy CP, Gutiérrez OM, Jimenez EY, et al.: State-of-the-art management of hyperphosphatemia in patients with CKD: An NKF-KDOQI controversies perspective. Am J Kidney Dis 77: 132–141, 2021 PubMed

• PubMed
Scialla JJ, Kendrick J, Uribarri J, Kovesdy CP, Gutiérrez OM, Jimenez EY, et al.: State-of-the-art management of hyperphosphatemia in patients with CKD: An NKF-KDOQI controversies perspective. Am J Kidney Dis 77: 132–141, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

Sampson M, Faria N, Powell JJ; PEACH study investigators: Efficacy and safety of PT20, an iron-based phosphate binder, for the treatment of hyperphosphataemia: A randomized, double-blind, placebo-controlled, dose-ranging, Phase IIb study in patients with haemodialysis-dependent chronic kidney disease. Nephrol Dial Transplant 36: 1399–1407, 2021 PubMed

• PubMed
Sampson M, Faria N, Powell JJ; PEACH study investigators: Efficacy and safety of PT20, an iron-based phosphate binder, for the treatment of hyperphosphataemia: A randomized, double-blind, placebo-controlled, dose-ranging, Phase IIb study in patients with haemodialysis-dependent chronic kidney disease. Nephrol Dial Transplant 36: 1399–1407, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

Larsson TE, Kameoka C, Nakajo I, Taniuchi Y, Yoshida S, Akizawa T, et al.: NPT-IIb inhibition does not improve hyperphosphatemia in CKD. Kidney Int Rep 3: 73–80, 2017 PubMed

• PubMed
Larsson TE, Kameoka C, Nakajo I, Taniuchi Y, Yoshida S, Akizawa T, et al.: NPT-IIb inhibition does not improve hyperphosphatemia in CKD. Kidney Int Rep 3: 73–80, 2017 PubMed)| false
• Search Google Scholar
• Export Citation

Cheng SC, Young DO, Huang Y, Delmez JA, Coyne DW: A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol 3: 1131–1138, 2008 PubMed

• PubMed
Cheng SC, Young DO, Huang Y, Delmez JA, Coyne DW: A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol 3: 1131–1138, 2008 PubMed)| false
• Search Google Scholar
• Export Citation

Young DO, Cheng SC, Delmez JA, Coyne DW: The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients. Perit Dial Int 29: 562–567, 2009 PubMed

• PubMed
Young DO, Cheng SC, Delmez JA, Coyne DW: The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients. Perit Dial Int 29: 562–567, 2009 PubMed)| false
• Search Google Scholar
• Export Citation

Ix JH, Isakova T, Larive B, Raphael KL, Raj DS, Cheung AK, et al.: Effects of nicotinamide and lanthanum carbonate on serum phosphate and fibroblast growth factor-23 in CKD: The COMBINE Trial. J Am Soc Nephrol 30: 1096–1108, 2019 PubMed

• PubMed
Ix JH, Isakova T, Larive B, Raphael KL, Raj DS, Cheung AK, et al.: Effects of nicotinamide and lanthanum carbonate on serum phosphate and fibroblast growth factor-23 in CKD: The COMBINE Trial. J Am Soc Nephrol 30: 1096–1108, 2019 PubMed)| false
• Search Google Scholar
• Export Citation

Ketteler M, Wiecek A, Rosenkranz AR, Pasch A, Rekowski J, Hellmann B, et al.: Efficacy and safety of a novel nicotinamide modified-release formulation in the treatment of refractory hyperphosphatemia in patients receiving hemodialysis—A randomized clinical trial. Kidney Int Rep 6: 594–604, 2020 PubMed

• PubMed
Ketteler M, Wiecek A, Rosenkranz AR, Pasch A, Rekowski J, Hellmann B, et al.: Efficacy and safety of a novel nicotinamide modified-release formulation in the treatment of refractory hyperphosphatemia in patients receiving hemodialysis—A randomized clinical trial. Kidney Int Rep 6: 594–604, 2020 PubMed)| false
• Search Google Scholar
• Export Citation

Ketteler M, Wiecek A, Rosenkranz AR, Ose C, Rekowski J, Lorenz H, et al.: Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase III randomised controlled NOPHOS trial [published online ahead of print Jun 25, 2022]. Nephrol Dial Transplant doi:10.1093/ndt/gfac206 PubMed

• PubMed
Ketteler M, Wiecek A, Rosenkranz AR, Ose C, Rekowski J, Lorenz H, et al.: Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase III randomised controlled NOPHOS trial [published online ahead of print Jun 25, 2022]. Nephrol Dial Transplant doi:10.1093/ndt/gfac206 PubMed)| false
• Search Google Scholar
• Export Citation

Tsuboi Y, Ohtomo S, Ichida Y, Hagita H, Ozawa K, Iida M, et al.: EOS789, a novel pan-phosphate transporter inhibitor, is effective for the treatment of chronic kidney disease-mineral bone disorder. Kidney Int 98: 343–354, 2020 PubMed

• PubMed
Tsuboi Y, Ohtomo S, Ichida Y, Hagita H, Ozawa K, Iida M, et al.: EOS789, a novel pan-phosphate transporter inhibitor, is effective for the treatment of chronic kidney disease-mineral bone disorder. Kidney Int 98: 343–354, 2020 PubMed)| false
• Search Google Scholar
• Export Citation

Hill Gallant KM, Stremke ER, Trevino LL, Moorthi RN, Doshi S, Wastney ME, et al.: EOS789, a broad-spectrum inhibitor of phosphate transport, is safe with an indication of efficacy in a phase 1b randomized crossover trial in hemodialysis patients. Kidney Int 99: 1225–1233, 2021 PubMed

• PubMed
Hill Gallant KM, Stremke ER, Trevino LL, Moorthi RN, Doshi S, Wastney ME, et al.: EOS789, a broad-spectrum inhibitor of phosphate transport, is safe with an indication of efficacy in a phase 1b randomized crossover trial in hemodialysis patients. Kidney Int 99: 1225–1233, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

King AJ, Siegel M, He Y, Nie B, Wang J, Koo-McCoy S, et al.: Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. Sci Transl Med 10: eaam6474, 2018 PubMed

• PubMed
King AJ, Siegel M, He Y, Nie B, Wang J, Koo-McCoy S, et al.: Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. Sci Transl Med 10: eaam6474, 2018 PubMed)| false
• Search Google Scholar
• Export Citation

Pergola PE, Rosenbaum DP, Yang Y, Chertow GM: A randomized trial of tenapanor and phosphate binders as a dual-mechanism treatment for hyperphosphatemia in patients on maintenance dialysis (AMPLIFY). J Am Soc Nephrol 32: 1465–1473, 2021 PubMed

• PubMed
Pergola PE, Rosenbaum DP, Yang Y, Chertow GM: A randomized trial of tenapanor and phosphate binders as a dual-mechanism treatment for hyperphosphatemia in patients on maintenance dialysis (AMPLIFY). J Am Soc Nephrol 32: 1465–1473, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

Elias RM, Alvares VRC, Moysés RMA: Phosphate removal during conventional hemodialysis: A decades-old misconception. Kidney Blood Press Res 43: 110–114, 2018 PubMed

• PubMed
Elias RM, Alvares VRC, Moysés RMA: Phosphate removal during conventional hemodialysis: A decades-old misconception. Kidney Blood Press Res 43: 110–114, 2018 PubMed)| false
• Search Google Scholar
• Export Citation

Chazot G, Lemoine S, Kocevar G, Kalbacher E, Sappey-Marinier D, Rouvière O, et al.: Intracellular phosphate and ATP depletion measured by magnetic resonance spectroscopy in patients receiving maintenance hemodialysis. J Am Soc Nephrol 32: 229–237, 2021 PubMed

• PubMed
Chazot G, Lemoine S, Kocevar G, Kalbacher E, Sappey-Marinier D, Rouvière O, et al.: Intracellular phosphate and ATP depletion measured by magnetic resonance spectroscopy in patients receiving maintenance hemodialysis. J Am Soc Nephrol 32: 229–237, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

Stremke ER, Trevino L, Doshi S, Moorthi RN, Hill Gallant KM, Moe SM: Postdialysis serum phosphate equilibrium in hemodialysis patients on a controlled diet and no binders. Hemodial Int 26: 255–263, 2022 PubMed

• PubMed
Stremke ER, Trevino L, Doshi S, Moorthi RN, Hill Gallant KM, Moe SM: Postdialysis serum phosphate equilibrium in hemodialysis patients on a controlled diet and no binders. Hemodial Int 26: 255–263, 2022 PubMed)| false
• Search Google Scholar
• Export Citation

Czaya B, Heitman K, Campos I, Yanucil C, Kentrup D, Westbrook D, et al.: Hyperphosphatemia increases inflammation to exacerbate anemia and skeletal muscle wasting independently of FGF23-FGFR4 signaling. eLife 11: e74782, 2022 PubMed

• PubMed
Czaya B, Heitman K, Campos I, Yanucil C, Kentrup D, Westbrook D, et al.: Hyperphosphatemia increases inflammation to exacerbate anemia and skeletal muscle wasting independently of FGF23-FGFR4 signaling. eLife 11: e74782, 2022 PubMed)| false
• Search Google Scholar
• Export Citation

Tiong MK, Cai MMX, Toussaint ND, Tan SJ, Pasch A, Smith ER: Effect of nutritional calcium and phosphate loading on calciprotein particle kinetics in adults with normal and impaired kidney function. Sci Rep 12: 7358, 2022 PubMed

• PubMed
Tiong MK, Cai MMX, Toussaint ND, Tan SJ, Pasch A, Smith ER: Effect of nutritional calcium and phosphate loading on calciprotein particle kinetics in adults with normal and impaired kidney function. Sci Rep 12: 7358, 2022 PubMed)| false
• Search Google Scholar
• Export Citation

Shiizaki K, Tsubouchi A, Miura Y, Seo K, Kuchimaru T, Hayashi H, et al.: Calcium phosphate microcrystals in the renal tubular fluid accelerate chronic kidney disease progression. J Clin Invest 131: e145693, 2021 PubMed

• PubMed
Shiizaki K, Tsubouchi A, Miura Y, Seo K, Kuchimaru T, Hayashi H, et al.: Calcium phosphate microcrystals in the renal tubular fluid accelerate chronic kidney disease progression. J Clin Invest 131: e145693, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

Jansson KP, Yu ASL, Stubbs JR: Contribution of phosphate and FGF23 to CKD progression. Curr Opin Nephrol Hypertens 31: 306–311, 2022 PubMed

• PubMed
Jansson KP, Yu ASL, Stubbs JR: Contribution of phosphate and FGF23 to CKD progression. Curr Opin Nephrol Hypertens 31: 306–311, 2022 PubMed)| false
• Search Google Scholar
• Export Citation

Toussaint ND, Pedagogos E, Lioufas NM, Elder GJ, Pascoe EM, Badve SV, et al.; IMPROVE-CKD Trial Investigators: A randomized trial on the effect of phosphate reduction on vascular end points in CKD (IMPROVE-CKD). J Am Soc Nephrol 31: 2653–2666, 2020 PubMed

• PubMed
Toussaint ND, Pedagogos E, Lioufas NM, Elder GJ, Pascoe EM, Badve SV, et al.; IMPROVE-CKD Trial Investigators: A randomized trial on the effect of phosphate reduction on vascular end points in CKD (IMPROVE-CKD). J Am Soc Nephrol 31: 2653–2666, 2020 PubMed)| false
• Search Google Scholar
• Export Citation

Lioufas NM, Pascoe EM, Hawley CM, Elder GJ, Badve SV, Block GA, et al.: Systematic review and meta-analyses of the effects of phosphate-lowering agents in nondialysis CKD. J Am Soc Nephrol 33: 59–76, 2022 PubMed

• PubMed
Lioufas NM, Pascoe EM, Hawley CM, Elder GJ, Badve SV, Block GA, et al.: Systematic review and meta-analyses of the effects of phosphate-lowering agents in nondialysis CKD. J Am Soc Nephrol 33: 59–76, 2022 PubMed)| false
• Search Google Scholar
• Export Citation

Simic P, Kim W, Zhou W, Pierce KA, Chang W, Sykes DB, et al.: Glycerol-3-phosphate is an FGF23 regulator derived from the injured kidney. J Clin Invest 130: 1513–1526, 2020 PubMed

• PubMed
Simic P, Kim W, Zhou W, Pierce KA, Chang W, Sykes DB, et al.: Glycerol-3-phosphate is an FGF23 regulator derived from the injured kidney. J Clin Invest 130: 1513–1526, 2020 PubMed)| false
• Search Google Scholar
• Export Citation

Courbon G, Francis C, Gerber C, Neuburg S, Wang X, Lynch E, et al.: Lipocalin 2 stimulates bone fibroblast growth factor 23 production in chronic kidney disease. Bone Res 9: 35, 2021 PubMed

• PubMed
Courbon G, Francis C, Gerber C, Neuburg S, Wang X, Lynch E, et al.: Lipocalin 2 stimulates bone fibroblast growth factor 23 production in chronic kidney disease. Bone Res 9: 35, 2021 PubMed)| false
• Export Citation

McKnight Q, Jenkins S, Li X, Nelson T, Marlier A, Cantley LG, et al.: IL-1β drives production of FGF-23 at the onset of chronic kidney disease in mice. J Bone Miner Res 35: 1352–1362, 2020 PubMed

• PubMed
McKnight Q, Jenkins S, Li X, Nelson T, Marlier A, Cantley LG, et al.: IL-1β drives production of FGF-23 at the onset of chronic kidney disease in mice. J Bone Miner Res 35: 1352–1362, 2020 PubMed)| false
• Search Google Scholar
• Export Citation

Akiyama KI, Miura Y, Hayashi H, Sakata A, Matsumura Y, Kojima M, et al.: Calciprotein particles regulate fibroblast growth factor-23 expression in osteoblasts. Kidney Int 97: 702–712, 2020 PubMed

• PubMed
Akiyama KI, Miura Y, Hayashi H, Sakata A, Matsumura Y, Kojima M, et al.: Calciprotein particles regulate fibroblast growth factor-23 expression in osteoblasts. Kidney Int 97: 702–712, 2020 PubMed)| false
• Search Google Scholar
• Export Citation

Ni P, Clinkenbeard EL, Noonan ML, Richardville JM, McClintick J, Hato T, et al.: Targeting fibroblast growth factor 23-responsive pathways uncovers controlling genes in kidney mineral metabolism. Kidney Int 99: 598–608, 2021 PubMed

• PubMed
Ni P, Clinkenbeard EL, Noonan ML, Richardville JM, McClintick J, Hato T, et al.: Targeting fibroblast growth factor 23-responsive pathways uncovers controlling genes in kidney mineral metabolism. Kidney Int 99: 598–608, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

Agoro R, White KE: Anemia and fibroblast growth factor 23 elevation in chronic kidney disease: Homeostatic interactions and emerging therapeutics. Curr Opin Nephrol Hypertens 31: 320–325, 2022 PubMed

• PubMed
Agoro R, White KE: Anemia and fibroblast growth factor 23 elevation in chronic kidney disease: Homeostatic interactions and emerging therapeutics. Curr Opin Nephrol Hypertens 31: 320–325, 2022 PubMed)| false
• Search Google Scholar
• Export Citation

Humalda JK, Yeung SMH, Geleijnse JM, Gijsbers L, Riphagen IJ, Hoorn EJ, et al.: Effects of potassium or sodium supplementation on mineral homeostasis: A controlled dietary intervention study. J Clin Endocrinol Metab 105: e3246–e3256, 2020 PubMed

• PubMed
Humalda JK, Yeung SMH, Geleijnse JM, Gijsbers L, Riphagen IJ, Hoorn EJ, et al.: Effects of potassium or sodium supplementation on mineral homeostasis: A controlled dietary intervention study. J Clin Endocrinol Metab 105: e3246–e3256, 2020 PubMed)| false
• Search Google Scholar
• Export Citation

Chen G, Liu Y, Goetz R, Fu L, Jayaraman S, Hu MC, et al.: α-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling. Nature 553: 461–466, 2018 PubMed

• PubMed
Chen G, Liu Y, Goetz R, Fu L, Jayaraman S, Hu MC, et al.: α-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling. Nature 553: 461–466, 2018 PubMed)| false
• Search Google Scholar
• Export Citation

Sharma S, Katz R, Ginsberg C, Bullen A, Vallon V, Thomson S, et al.: Renal clearance of fibroblast growth factor-23 (FGF23) and its fragments in humans. J Bone Miner Res 37: 1170–1178, 2022 PubMed

• PubMed
Sharma S, Katz R, Ginsberg C, Bullen A, Vallon V, Thomson S, et al.: Renal clearance of fibroblast growth factor-23 (FGF23) and its fragments in humans. J Bone Miner Res 37: 1170–1178, 2022 PubMed)| false
• Search Google Scholar
• Export Citation

Graves JM, Vallejo JA, Hamill CS, Wang D, Ahuja R, Patel S, et al.: Fibroblast growth factor 23 (FGF23) induces ventricular arrhythmias and prolongs QTc interval in mice in an FGF receptor 4-dependent manner. Am J Physiol Heart Circ Physiol 320: H2283–H2294, 2021 PubMed

• PubMed
Graves JM, Vallejo JA, Hamill CS, Wang D, Ahuja R, Patel S, et al.: Fibroblast growth factor 23 (FGF23) induces ventricular arrhythmias and prolongs QTc interval in mice in an FGF receptor 4-dependent manner. Am J Physiol Heart Circ Physiol 320: H2283–H2294, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

Yanucil C, Kentrup D, Campos I, Czaya B, Heitman K, Westbrook D, et al.: Soluble α-klotho and heparin modulate the pathologic cardiac actions of fibroblast growth factor 23 in chronic kidney disease. Kidney Int 102: 261–279, 2022 PubMed

• PubMed
Yanucil C, Kentrup D, Campos I, Czaya B, Heitman K, Westbrook D, et al.: Soluble α-klotho and heparin modulate the pathologic cardiac actions of fibroblast growth factor 23 in chronic kidney disease. Kidney Int 102: 261–279, 2022 PubMed)| false
• Search Google Scholar
• Export Citation

Wang AA, Cai X, Srivastava A, Prasad PV, Sprague SM, Carr J, et al.: Abnormalities in Cardiac Structure and Function among Individuals with CKD: The COMBINE Trial. Kidney360 3: 258–268, 2021 PubMed

• PubMed
Wang AA, Cai X, Srivastava A, Prasad PV, Sprague SM, Carr J, et al.: Abnormalities in Cardiac Structure and Function among Individuals with CKD: The COMBINE Trial. Kidney360 3: 258–268, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

Komaba H, Fuller DS, Taniguchi M, Yamamoto S, Nomura T, Zhao J, et al.: Fibroblast growth factor 23 and mortality among prevalent hemodialysis patients in the Japan Dialysis Outcomes and Practice Patterns study. Kidney Int Rep 5: 1956–1964, 2020 PubMed

• PubMed
Komaba H, Fuller DS, Taniguchi M, Yamamoto S, Nomura T, Zhao J, et al.: Fibroblast growth factor 23 and mortality among prevalent hemodialysis patients in the Japan Dialysis Outcomes and Practice Patterns study. Kidney Int Rep 5: 1956–1964, 2020 PubMed)| false
• Search Google Scholar
• Export Citation

Mehta RC, Cho ME, Cai X, Lee J, Chen J, He J, et al; CRIC Study Investigators: Iron status, fibroblast growth factor 23 and cardiovascular and kidney outcomes in chronic kidney disease. Kidney Int 100: 1292–1302, 2021 PubMed

• PubMed
Mehta RC, Cho ME, Cai X, Lee J, Chen J, He J, et al; CRIC Study Investigators: Iron status, fibroblast growth factor 23 and cardiovascular and kidney outcomes in chronic kidney disease. Kidney Int 100: 1292–1302, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

De Jong MA, Eisenga MF, van Ballegooijen AJ, Beulens JWJ, Vervloet MG, Navis G, et al.: Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: The Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Nephrol Dial Transplant 36: 121–128, 2021 PubMed

• PubMed
De Jong MA, Eisenga MF, van Ballegooijen AJ, Beulens JWJ, Vervloet MG, Navis G, et al.: Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: The Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Nephrol Dial Transplant 36: 121–128, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

El Ters M, Lu P, Mahnken JD, Stubbs JR, Zhang S, Wallace DP, et al.: Prognostic value of fibroblast growth factor 23 in autosomal dominant polycystic kidney disease. Kidney Int Rep 6: 953–961, 2021 PubMed

• PubMed
El Ters M, Lu P, Mahnken JD, Stubbs JR, Zhang S, Wallace DP, et al.: Prognostic value of fibroblast growth factor 23 in autosomal dominant polycystic kidney disease. Kidney Int Rep 6: 953–961, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

Isakova T, Cai X, Lee J, Mehta R, Zhang X, Yang W, et al; CRIC Study Investigators: Longitudinal evolution of markers of mineral metabolism in patients with CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 75: 235–244, 2020 PubMed

• PubMed
Isakova T, Cai X, Lee J, Mehta R, Zhang X, Yang W, et al; CRIC Study Investigators: Longitudinal evolution of markers of mineral metabolism in patients with CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 75: 235–244, 2020 PubMed)| false
• Search Google Scholar
• Export Citation

Ishigami J, Grams ME, Michos ED, Lutsey PL, Matsushita K: 25-hydroxyvitamin D, fibroblast growth factor 23, and risk of acute kidney injury over 20 years of follow-up. Kidney Int Rep 6: 1299–1308, 2021 PubMed

• PubMed
Ishigami J, Grams ME, Michos ED, Lutsey PL, Matsushita K: 25-hydroxyvitamin D, fibroblast growth factor 23, and risk of acute kidney injury over 20 years of follow-up. Kidney Int Rep 6: 1299–1308, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

Desbiens LC, Sidibé A, Ung RV, Mac-Way F: FGF23-Klotho axis and fractures in patients without and with early CKD: A case-cohort analysis of CARTaGENE. J Clin Endocrinol Metab 107: e2502–e2512, 2022 PubMed

• PubMed
Desbiens LC, Sidibé A, Ung RV, Mac-Way F: FGF23-Klotho axis and fractures in patients without and with early CKD: A case-cohort analysis of CARTaGENE. J Clin Endocrinol Metab 107: e2502–e2512, 2022 PubMed)| false
• Search Google Scholar
• Export Citation

Hughes-Austin JM, Katz R, Semba RD, Kritchevsky SB, Bauer DC, Sarnak MJ, et al.: Biomarkers of bone turnover identify subsets of chronic kidney disease patients at higher risk for fracture. J Clin Endocrinol Metab 105: e2903–e2911, 2020 PubMed

• PubMed
Hughes-Austin JM, Katz R, Semba RD, Kritchevsky SB, Bauer DC, Sarnak MJ, et al.: Biomarkers of bone turnover identify subsets of chronic kidney disease patients at higher risk for fracture. J Clin Endocrinol Metab 105: e2903–e2911, 2020 PubMed)| false
• Search Google Scholar
• Export Citation